Kadimastem Has Successfully Completed an IPO and Raised $5.5 Million USD

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

NESS ZIONA, Israel--(BUSINESS WIRE)--Kadimastem Ltd. (TASE:KDST), focusing on the development and industrial commercialization of products based on human embryonic stem cells, announced today the closing of its initial public offering on the Tel Aviv Stock Exchange. The tender, which included 3.1 million shares and 2 option series, recorded demands in the scope of approximately 5.5 million USD. The tender price closed at 1.81 USD per share.

Help employers find you! Check out all the jobs and post your resume.

Back to news